Sofinnova Investments portfolio
Concentrated managerInvestment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Sofinnova Investments reported a $1.9 bn portfolio of 53 positions to the SEC as of the end of Q2 2026. Its largest positions are NTRA, VERA, GMAB. During the quarter it opened Gilead Sciences and exited Astrazeneca and Biogen.
Sections with a free account
What changed this quarter
56 positions with a change (9 new, 12 added to, 17 trimmed, 18 sold); also, 1 entered through an IPO, 1 exited through an acquisition or merger, 1 entered through a spin-off. 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Newly listedSeaport TherapeuticsSPTX4.1% of the portfolio
It started trading this quarter: it appears in a 13F for the first time. The filing does not say whether the manager already held it before the listing, so it is not counted as a purchase.
- Genmab A/S+438%more sharesIncreased1.0% → 5.9%
- Astrazeneca−4.5 ppof portfolioSold out4.5% → —
- Bristol-myers Squibb−56%fewer sharesReduced6.0% → 2.7%
- Jazz Pharmaceuticals−39%fewer sharesReduced5.7% → 4.7%
- Ultragenyx Pharmaceutical−45%fewer sharesReduced3.3% → 3.1%
- United Therapeutics−52%fewer sharesReduced4.8% → 2.2%
- Gilead Sciences+2.2 ppof portfolioNew— → 2.3%
- Biogen−2.1 ppof portfolioSold out2.1% → —
- Celcuity−2.1 ppof portfolioSold out2.1% → —
- Cogent Biosciences−51%fewer sharesReduced4.1% → 2.1%
- Alcon−65%fewer sharesReduced2.8% → 0.9%
- BridgeBio Pharma−1.5 ppof portfolioSold out1.5% → —
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- NateraNTRA22.5%
- Vera TherapeuticsVERA6.4%
- Genmab A/SGMAB5.9%
- Jazz PharmaceuticalsJAZZ4.7%
- Rapport TherapeuticsRAPP4.2%
- Seaport TherapeuticsSPTX4.1%
- Arrivent BiopharmaAVBP3.1%
- Ultragenyx PharmaceuticalRARE3.1%
- Bioage LabsBIOA3.0%
- Bristol-myers SquibbBMY2.7%
- Indivior PharmaceuticalsSUPN2.6%
- Rhythm PharmaceuticalsRYTM2.4%
- Gilead SciencesGILD2.3%
- United TherapeuticsUTHR2.2%
- Cogent BiosciencesCOGT2.1%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 100%
How its portfolio changed (8 quarters)
Q2 2026: 53
Q2 2026: 60%
Q2 2026: 25.8%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Declared options (4)
Besides stocks, Sofinnova Investments declared 1 put (they gain if the stock falls) and 3 calls (they gain if it rises) with a notional of $62.2M. The 13F reports the value of the underlying shares, not the premium paid, so these figures look large and are not added to the portfolio. Nor does it say whether the option is bought or written, or its strike or expiry: it may be a hedge.
- CALLUltragenyx PharmaceuticalRARE$16.7M
- CALLIntuitive SurgicalISRGnew this quarter$15.9M
- CALLGlobus MedicalGMEDnew this quarter$15.8M
- PUTExelixisEXEL$13.8M
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- Trinity Street Asset Management LLPInvestment firm · $1.9 bn
- Keystone Investors PTEInvestment firm · $1.9 bn
- Cacti Asset ManagementInvestment firm · $1.9 bn
- Spyglass Capital ManagementInvestment firm · $1.8 bn
- Greenhouse Funds LLLPInvestment firm · $1.9 bn
- Broadwood CapitalInvestment firm · $1.9 bn